Comparator issue strikes again; Germany's IQWiG in doubt over GSK's Trobalt
This article was originally published in Scrip
Executive Summary
The issue over comparators has cast a shadow over another drug undergoing Germany's early benefit assessment, GlaxoSmithKline/Valeant's Trobalt (retigabine). IQWiG, the Institute for Quality and Efficiency in Healthcare, has said that there is no proof of added benefit for the anti-epileptic after the firm chose different comparators than those wanted by the agency.